Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder

European Urology

Volumn 36, Issue 6, 1999, Pages 576-581

  Witjes, W P J ^a   Konig, M ^a   Boeminghaus, F P ^a   Hall, R R ^a   Schulman, C C ^a   Zurlo, M ^a   Fittipaldo, A ^a   Riggi, M ^a   Debruyne, F M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Bropirimine; Carcinoma in situ; Immunomodulators

Indexed keywords

BCG VACCINE; BROPIRIMINE; IMMUNOMODULATING AGENT;

ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CARCINOMA IN SITU; CLINICAL TRIAL; COUGHING; CYTOLOGY; DIARRHEA; DYSURIA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; BCG VACCINE; CARCINOMA IN SITU; CHI-SQUARE DISTRIBUTION; CYTOSINE; FEMALE; HUMANS; MALE; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0032699256     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020051     Document Type: Article

References (15)